Nymox Pharmaceutical Corporation (NASDAQ:NYMX) specializes in the research and development of novel drugs and diagnostic products for the aging population. Nymox Pharmaceutical’s lead drug candidate is NX-1207, a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH). NX-1207 is currently in Phase 3 trials in the United States.
Delivery Technology Solutions, Inc. (DTSL.PK) – Delivery Technology Solutions, Inc., is the leader in providing comprehensive custom-developed catering/delivery solutions to industries throughout North America, including restaurants, retail and others.
